This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Rent or buy this article
Prices vary by article type
from$1.95
to$39.95
Prices may be subject to local taxes which are calculated during checkout
References
Cohn JN and Tognoni G (2001) Forth Valsartan Heart Failure Trial Investigators. A randomized trial of the angiotensin-receptor blocker valsartan in chronic heart failure. N Engl J Med 345: 1667–1675
Pfeffer MA et al. (2003) Valsartan, Captopril, or Both in Myocardial Infarction Complicated by Heart Failure, Left Ventricular Dysfunction, or Both. N Engl J Med 349: 1893–1906
Pitt B et al. (2003) Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med 348: 1309–1321
Pitt B et al. (2003) The effect of spironolactone on morbidity and mortality in patients with severe heart failure. N Engl J Med 341: 709–717
Acknowledgements
The synopsis was written by Hannah Camm, Associate Editor, Nature Clinical Practice.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
B Pitt is a consultant for Novartis and AstraZeneca.
Rights and permissions
About this article
Cite this article
Pitt, B. Should chronic heart failure patients with reduced left-ventricular ejection fraction receive angiotensin-receptor blockers?. Nat Rev Cardiol 2, 70–71 (2005). https://doi.org/10.1038/ncpcardio0099
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1038/ncpcardio0099